INHALED DRY POWDER BUDESONIDE

Clinical Indication

Covid 19 treatment

Comments

No longer recommended for Covid treatment outside of a trial in line with CAS 103185

 

Date of classification

April 2021

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.